Drawing for DATAOME TECHNOLOGY

USPTO serial 87048099

DATAOME TECHNOLOGY

Reviewed by CopyMark Law Group

Reg. 6153448Status 700Renewal
Filing date
Status date
Registration date
Sep 15, 2020
Examiner
BLANDU, FLORENTINA
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DATAOME TECHNOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,144*

Plus Government fees of $2,550

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Peter T. Wakiyama

Peter T. Wakiyama PEPPER HAMILTON LLP18TH AND ARCH STREETS3000 TWO LOGAN SQUAREPHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information on humans; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for mobile devices, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humansACTIVENov 1, 2019
035Business consulting and research services for employers in the field of employee benefits in the nature of offering medical and health care plans to employees and their family members and domestic partners for medical and health care diagnostic and treatment support programsACTIVENov 1, 2019
036Financial administration of programs and services for payment and reimbursement of employee benefits in the nature of medical and health care diagnostic and treatment support programs, for employees and their family members and domestic partnersACTIVENov 1, 2019
038Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to searchable online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposesACTIVENov 1, 2019
042Scientific consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; Scientific consulting and research services in the nature of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing, and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, medical health information patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; designing and developing searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing a web site featuring non-downloadable software and algorithms for use by physicians, clinicians and other health care professionals, laboratory personnel, consultants, scientists and other researchers for conducting scientific, medical and pharmaceutical research; providing a web site featuring software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; providing online, non-downloadable mobile and web applications for mobile devices, namely, smart phones and tablets, for accessing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology for scientific research purposes; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; research services in the fields of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing a web site featuring online non-downloadable computer software and algorithms for medical diagnostic and treatment purposes; providing a web site featuring online non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing a web site featuring online non-downloadable mobile applications for mobile devices, namely, smart phones and tablets, and non-downloadable web applications accessible through the Internet all for retrieval of information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnologyACTIVENov 1, 2019
044Medical consulting in the fields of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocolsACTIVENov 1, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 15, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 15, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 11, 2020SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Aug 9, 2020CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 22, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 16, 2020IUAFUSE AMENDMENT FILED—
Jul 16, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jan 15, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2020EX5GSOU EXTENSION 5 GRANTED—
Jan 9, 2020EXT5SOU EXTENSION 5 FILED—
Jan 9, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 27, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 25, 2019EX4GSOU EXTENSION 4 GRANTED—
Jul 25, 2019EXT4SOU EXTENSION 4 FILED—
Jul 25, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 29, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 25, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 25, 2019EX3GSOU EXTENSION 3 GRANTED—
Jan 25, 2019EXT3SOU EXTENSION 3 FILED—
Jan 25, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 27, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 25, 2018EX2GSOU EXTENSION 2 GRANTED—
Jul 25, 2018EXT2SOU EXTENSION 2 FILED—
Jul 25, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 25, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 9, 2018DOCKASSIGNED TO EXAMINER—
Feb 21, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 20, 2018EX1GSOU EXTENSION 1 GRANTED—
Feb 20, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 5, 2018NREVNOTICE OF REVIVAL - E-MAILED—
Feb 5, 2018TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Feb 5, 2018PETGPETITION TO REVIVE-GRANTED—
Feb 5, 2018PROATEAS PETITION TO REVIVE RECEIVED—
Jan 25, 2018EXT1SOU EXTENSION 1 FILED—
Jul 25, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 30, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 30, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 10, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 26, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 24, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 4, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 4, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 30, 2017ALIEASSIGNED TO LIE—
Mar 15, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 15, 2016GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Sep 15, 2016GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Sep 15, 2016CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Sep 8, 2016DOCKASSIGNED TO EXAMINER—
Jun 1, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 27, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance